AxoGen (AXGN) was Upgraded by Lake Street to ” Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 11 from a previous price target of $9 . Earlier the firm had a rating of “Hold ” on the company shares. Lake Street advised their investors in a research report released on Nov 22, 2016.
Many Wall Street Analysts have commented on AxoGen. Company shares were Reiterated by Wedbush on Nov 7, 2016 to “Outperform”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .Lake Street Downgraded AxoGen on Nov 3, 2016 to ” Hold”, Price Target of the shares are set at $9.
AxoGen opened for trading at $8.75 and hit $8.9 on the upside on Monday, eventually ending the session at $8.9, with a gain of 1.71% or 0.15 points. The heightened volatility saw the trading volume jump to 1,56,153 shares. Company has a market cap of $293 M.
In a different news, on Oct 14, 2016, Amy Mcbride Wendell (director) purchased 13,333 shares at $7.50 per share price. According to the SEC, on Oct 14, 2016, Peter J Mariani (CFO) purchased 3,333 shares at $7.50 per share price. On Oct 14, 2016, Kevin Leach (Vice President Marketing) purchased 2,000 shares at $7.50 per share price, according to the Form-4 filing with the securities and exchange commission.